



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-15. (Cancelled)

16. (Currently amended) A lysate obtainable by ~~the process of claim 4~~ a process comprising the steps:

(a) inducing necrosis of tumor cells by subjecting the cells to a temperature of more than 41.2°C for at least 15 minutes; and

(b) lysing said necrotic tumor cells so as to obtain a lysate.

17. (Original) Dendritic cells loaded with the lysate of claim 16.

18. (Original) A composition comprising a lysate of claim 16 or dendritic cells of claim 17.

19. (Original) The composition of claim 18, which is a pharmaceutical composition.

20. (Original) The composition of claim 18, which is a vaccine composition.

21. (Previously presented) The pharmaceutical composition of claim 19, which is optionally combined with an adjuvant.

22. (Previously presented) The dendritic cells of claim 17, wherein said dendritic cells are immature.

23. (Previously presented) The dendritic cells of claim 17, wherein said dendritic cells are mature.

24. (Currently amended) A ~~method for the production of a vaccine composition comprising the step of combining a cell lysate of claim 16 or the dendritic cells of claim 17~~ and ~~[[with]]~~ an adjuvant.

25-31. (Cancelled)

32. (Previously presented) The composition of claim 18, wherein the dendritic cells are immature.

33. (Previously presented) The composition of claim 20, wherein the dendritic cells are mature.

34-35. (Cancelled)

36. (New) The lysate of claim 16, wherein necrosis is induced in tumor cells selected from the group consisting of tumor cell lines, cells derived from primary tumor material, cells derived from cell populations of primary tumor material and/or metastases including micrometastases.

37. (New) The lysate of claim 16, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature of more than 42°C.

38. (New) The lysate of claim 16, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature in the range of 45°C to 55°C.

39. (New) The lysate of claim 16, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature in the range of 45.5°C to 47°C.

40. (New) The lysate of claim 16, wherein induction of necrosis is performed in the range of 2 to 3 hours.

41. (New) The lysate of claim 16, wherein more than 40% of the tumor cells are necrotic after induction of necrosis.

42. (New) The lysate of claim 16, wherein more than 70% of the tumor cells are necrotic after induction of necrosis.

43. (New) The lysate of claim 1, wherein the tumor cells are genetically engineered, mutated or infected by oncogenic viruses.

44. (New) The lysate of claim 16, wherein the tumor cells are autologous and from the same or from different tissues, organs or cell origin in a species.

45. (New) The lysate of claim 16, wherein the tumor cells are allogenic.

46. (New) The lysate of claim 16, wherein the tumor cells are syngenic.

47. (New) The lysate of claim 16, wherein the tumor cells are xenogenic.

48. (New) The lysate of claim 16, wherein more than one type of tumor cell is used and wherein the tumor cells are from the same or different individuals, tissues, cell types or tumors.

49. (New) The lysate of claim 16, wherein the tumor cells are NM-F9 cells (DSMZ deposit No DSM ACC2606) or NM-D4 cells (DSMZ deposit No. DSM ACC2605).